Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

Fig. 5

a MTS assay showing the viability of A549 after 72-h treatment with a low dose of cisplatin (Cis; 10 μM) and a low dose of pirfenidone (Pirf; 0.5 mg/mL). Untrt, untreated. b Annexin V/PI flow cytometric analysis in A549 cells after 48 h of treatment showing increased apoptosis when agents were combined (cisplatin + pirfenidone) compared with control. c Immunoblot analysis of PARP cleavage showing significant PARP cleavage in the combination of both drugs when compared to each drug alone. *P < 0.05

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us